Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 6:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 360 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Spray Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of GSP 301 Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (SAR)

NCT02870205
View directory record Official record
Conditions
Seasonal Allergic Rhinitis (SAR)
Interventions
GSP 301 NS, GOM-NS, GMM-2 NS, GSP 301 placebo NS
Drug
Lead sponsor
Glenmark Specialty S.A.
Industry
Eligibility
12 Years and older
Enrollment
1,176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
43
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 33 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2018 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Results available

Comparator Study Evaluating Patient Experience And Preference Of FFNS vs. FPNS

NCT00519636
View directory record Official record
Conditions
Rhinitis, Allergic, Perennial
Interventions
FPNS, FFNS, placebo FFNS, placebo FPNS
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
28
States / cities
Birmingham, Alabama • Phoenix, Arizona • Long Beach, California + 20 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2016 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Evaluation of the Sensory Attributes of Olopatadine 0.6% and Azelastine 137mcg Nasal Sprays in Patients w/Allergic Rhinitis

NCT00772304
View directory record Official record
Conditions
Allergic Rhinitis
Interventions
Olopatadine 0.6% / Azelastine 137 mcg
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Study Of Adults And Adolescents With Vasomotor Rhinitis

NCT00117325
View directory record Official record
Conditions
Rhinitis, Vasomotor
Interventions
GW685698X
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
12 Years and older
Enrollment
352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
38
States / cities
Beverly Hills, California • Huntington Beach, California • Mission Viejo, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2018 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Two Nasal Sprays to Treat Seasonal Allergies

NCT00720278
View directory record Official record
Conditions
Seasonal Allergic Rhinitis
Interventions
0.15% azelastine hydrochloride 1644 mcg daily, 0.1% azelastine hydrochloride 1096 mcg daily, Placebo
Drug
Lead sponsor
Meda Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
526 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
29
States / cities
Oxford, Alabama • Encinitas, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2010 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine Safety and Efficacy of B244 in Subjects With Mild to Moderate Rosacea

NCT03590366
View directory record Official record
Conditions
Rosacea
Interventions
B244, Vehicle
Biological
Lead sponsor
AOBiome LLC
Industry
Eligibility
18 Years and older
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
9
States / cities
Clearwater, Florida • Miami, Florida • Miramar, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2022 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal Spray

NCT01136642
View directory record Official record
Conditions
Drug Addiction, Nicotine Dependence
Interventions
Nicotrol
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Fentanyl Pectin Nasal Spray (FNPS) for Exercise-Induced Breakthrough Dyspnea

NCT01832402
View directory record Official record
Conditions
Advanced Cancers
Interventions
Fentanyl Pectin Nasal Spray, Placebo Nasal Spray, Walk Test, Questionnaires, Mental Ability Tests
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 20, 2026, 6:31 AM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

A Prospective, Open-Label Study Evaluating the Effectiveness of Gepants for Acute Treatment of Migraine in the Emergency Department

NCT07667621
View directory record Official record
Conditions
Migraine, Migraine Disease, Migraine in Adults, Migraine Headache, Acute Migraine, Migraine Without Aura, Migraine With Aura
Interventions
Rimegepant, Zavegepant
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Terminated Phase 3 Interventional Results available

Safety and Effectiveness of Nabiximols Oromucosal Spray as Add-on Therapy in Participants With Spasticity Due to Multiple Sclerosis

NCT04203498
View directory record Official record
Conditions
Multiple Sclerosis (MS)
Interventions
Nabiximols, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Birmingham, Alabama • Port Charlotte, Florida • Tampa, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Clinical Trial to Evaluate OC-01 Nasal Spray in Subjects With Neurotrophic Keratopathy

NCT04957758
View directory record Official record
Conditions
Neurotrophic Keratopathy
Interventions
OC-01 (varenicline) nasal spray 1.2 mg/ml, Placebo (vehicle) nasal spray
Drug
Lead sponsor
Oyster Point Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
113 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
31
States / cities
Dothan, Alabama • Irvine, California • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

Market Potential of Carbon Dioxide Nasal Spray

NCT02113449
View directory record Official record
Conditions
Nasal Congestion
Interventions
Carbon Dioxide
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
4
States / cities
Chandler, Arizona • Pinellas Park, Florida • Paramus, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 20, 2026, 6:31 AM EDT
Active, not recruiting Phase 3 Interventional

Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4)

NCT06615557
View directory record Official record
Conditions
Social Anxiety Disorder (SAD)
Interventions
Fasedienol Nasal Spray, Placebo Nasal Spray
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
26
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bellflower, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating the Bioavailability of Miricorilant With Optional Food Effect Assessment in Healthy Adult Subjects

NCT07240116
View directory record Official record
Conditions
Healthy
Interventions
Miricorilant Treatment A, Miricorilant Treatment B, Miricorilant Treatment C, Miricorilant Treatment D
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Treating Contact Lens Discomfort With Varenicline Solution Nasal Spray 0.03mg

NCT07705893
View directory record Official record
Conditions
Dry Eye
Interventions
Tyrvaya
Drug
Lead sponsor
Ocular Aesthetics, LLC dba Ocular Clinical Trials
Other
Eligibility
18 Years to 99 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Assessment of the Single Dose Pharmacokinetics and Tolerability of Sativex in Patients With Impaired Hepatic Function and Healthy Patients

NCT01887301
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Sativex
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
2
States / cities
Anaheim, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 20, 2022 · Synced Oct 20, 2026, 6:31 AM EDT
Recruiting Not applicable Interventional

Does Ethyl Chloride Spray Work?

NCT06651788
View directory record Official record
Conditions
Injection Fear, Injection Pain Prevention, Injection Complication
Interventions
Ethyl Chloride, Cold Saline Spray
Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Study of the Effects of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol on Hypothalamic-Pituitary-Adrenal (HPA) Axis

NCT01033825
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
Ciclesonide HFA Nasal Aerosol 320 mcg, Ciclesonide HFA Nasal Aerosol 160 mcg, HFA Nasal Aerosol placebo, Ciclesonide Aqueous Nasal Spray 200 mcg, AQ Nasal Spray Placebo, Placebo plus Dexamethasone HFA, Placebo AQ plus Dexamethasone 6 mg
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
6
States / cities
Stockbridge, Georgia • North Dartmouth, Massachusetts • Minneappolis, Minnesota + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2012 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 3 Interventional Results available

Long Term Safety of Sativex Oromucosal Spray (Sativex®; Nabiximols) as Adjunctive Therapy in Patients With Uncontrolled Persistent Chronic Cancer Related Pain

NCT01337089
View directory record Official record
Conditions
Pain, Advanced Cancer
Interventions
Nabiximols
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
660 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
37
States / cities
Phoenix, Arizona • El Cajon, California • Gilroy, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 20, 2026, 6:31 AM EDT
Recruiting Phase 2 Interventional

Spray Cryotherapy for the Management of Benign Central Airway Stenosis (Cryo-BAS)

NCT06761170
View directory record Official record
Conditions
Stenosis of Trachea
Interventions
Spray cryo therapy, Standard of Care (SOC)
Procedure
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Early Phase 1 Interventional

Ethyl Chloride Spray to Reduce Pain From Local Anesthesia During Mohs Micrographic Surgery

NCT06920381
View directory record Official record
Conditions
Surgery
Interventions
Gebauer's Ethyl Chloride Topical Spray
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 2 Interventional Results available

PH94B in the Treatment of Adjustment Disorder With Anxiety

NCT04404192
View directory record Official record
Conditions
Adjustment Disorder With Anxious Mood
Interventions
PH94B, Placebo
Drug
Lead sponsor
VistaGen Therapeutics, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
2
States / cities
Watertown, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 4 Interventional Results available

A 6 Month Safety Study Of Ciclesonide Nasal Aerosol (Zetonna®) And Ciclesonide Nasal Spray (Omnaris®) In Subjects 12 Years And Older With Perennial Allergic Rhinitis (PAR)

NCT01654536
View directory record Official record
Conditions
Perennial Allergic Rhinitis
Interventions
ciclesonide nasal aerosol, ciclesonide nasal spray
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
12 Years and older
Enrollment
737 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
31
States / cities
Mission Viejo, California • Orange, California • San Diego, California + 26 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2014 · Synced Oct 20, 2026, 6:31 AM EDT
Completed Phase 4 Interventional

Study of Nasal Irrigation Versus Nasal Spray for Chronic Nasal and Sinus Symptoms

NCT00318006
View directory record Official record
Conditions
Chronic Rhinosinusitis
Interventions
saline irrigation, saline spray
Procedure
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 30, 2015 · Synced Oct 20, 2026, 6:31 AM EDT